# Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma

> **NCT00384553** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University of Magdeburg** · enrollment: 30 (—)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** DHAP
- **DRUG:** TEC
- **DRUG:** autologous stem cell transplantation

## Key facts

- **NCT ID:** NCT00384553
- **Lead sponsor:** University of Magdeburg
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2010-06
- **Target enrollment:** 30 (—)
- **Last updated:** 2006-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00384553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00384553, "Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00384553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*